Muscle Atrophy Pipeline Report: Evaluates Market on Mechanism of Action (MoA), Drug Target, Route of Administration (RoA) and Molecule Type

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Muscle Atrophy – Pipeline Review, H1 2018, provides an overview of the Muscle Atrophy (Musculoskeletal Disorders) pipeline landscape.

Pune, India – March 29, 2018 /MarketersMedia/ —

Muscle atrophy is the wasting or loss of muscle tissue. Symptoms of muscle atrophy include muscle damage, pain, weak muscles, loss of movement, facial weakness and numbness or tingling in arms or legs. Causes include aging, nerve diseases, stroke, motor neuropathy, muscular dystrophy and arthritis. Treatment includes exercise, dietary changes and surgery.
Report Source: https://www.themarketreports.com/report/muscle-atrophy-pipeline-review-h1-2018
Scope
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Muscle Atrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Muscle Atrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders)
Purchase this report at: https://www.themarketreports.com/report/buy-now/1036787
Reasons To Buy
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Muscle Atrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
• Escape Therapeutics Inc
• K-Stemcell Co Ltd
• Milo Biotechnology LLC
• Shionogi & Co Ltd
• Spherium Biomed SL
• Teijin Pharma Ltd
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1036787

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/muscle-atrophy-pipeline-report-evaluates-market-on-mechanism-of-action-moa-drug-target-route-of-administration-roa-and-molecule-type/322604

For more information, please visit https://www.themarketreports.com/report/muscle-atrophy-pipeline-review-h1-2018%20%20

Source: MarketersMedia

Release ID: 322604